EP32 – The ratio of serum Thyroglobulin to Tg Antibodies (Tg/TgAb) is useful as a surrogate tumor-marker of differentiated thyroid carcinoma


    Akiyama, Ichiro1; Usui, Yoshiyuki1
    1 Surgery, Okayama National Hospital, Okayama, Japan


    Background: Although Tg is an established tumor marker used in the management of patients with DTC, it is not useful for TgAb-positive case.

    Purpose and Methods: We will show the cases of DTC who underwent total thyroidectomy to describe the clinical utility of the ratio of Tg/TgAb.

    Results: In the case of rapid progression disease (PD), Tg increase much faster than TgAb and it makes Tg/TgAb higher.
    On the other hands, in the case of rapid partial response (PR) due to effective treatment, Tg decrease much faster than TgAb and it makes Tg/TgAb lower.
    In the case of stable disease (SD), mild PD or PR, Tg/TgAb is low and stable, because the productivity of Tg and TgAb is balanced.

    Discussion: Even if TgAb interfere Tg, Tg/TgAb may reflects the disease progression because TgAb change much slowly compare with Tg. It is reported that half-life period of TgAb is about 6 months to 3 years, and it is much longer than Tg. In addition, Tg/TgAb might useful to evaluate the indication of tyrosine kinase inhibitor.
    Conclusion: In the cases for TgAb-positive patients, especially long SD cases, the ratio of Tg/TgAb is useful as a surrogate tumor-marker of DTC.


Leave a Reply

  • Upcoming Events


    World Congress on Thyroid Cancer 3.5
    June 20 – 22, 2019
    Rome, Italy

    World Congress on Thyroid Cancer 4.0
    July 29 – August 1, 2021
    Boston, Massachusetts


  • WCTC3.5 Steering Committee:


    Rocco Bellatone, Co-Chair
    Celestino Lombardi, Co-Chair
    Gregory W. Randolph, MD
    Bryan McIver, MD
    Jeremy Freeman, MD
    Ian J. Witterick, MD
    Ashok R. Shaha, MD
    Jatin P. Shah, MD